- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
>Human Cell Expressed
>Rat Syndecan-1 / SDC1 / CD138 Protein (Fc Tag)
|Catalog||Size (Price)||Quantity||In Stock||Operation|
Syndecan 1 Protein Datasheet
SDC1 / Syndecan-1 / SYND1 Protein Price Inquiry ( Available Sizes )
SDC1 / Syndecan-1 / SYND1 Protein Product Information
|Synonym :||SDC1, Synd1|
A DNA sequence encoding the rat SDC1 (P26260) (Met1-Lys253) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
|Expression Host:||Human Cells|
SDC1 / Syndecan-1 / SYND1 Protein QC Testing
|Purity:||> 90% as determined by SDS-PAGE||SDS-PAGE:
SDC1 / Syndecan-1 / SYND1 protein
|1. Measured by its binding ability in a functional ELISA. Immobilized human PTN (Cat:10288-HNAB) at 10 μg/ml (100 μl/well) can bind rat SDC1-Fc (Cat:80344-R02H), The EC50 of rat SDC1-Fc (Cat:80344-R02H) is 0.35-0.81 μg/ml.
2. Measured by its binding ability in a functional ELISA. Immobilized mouse PTN (Cat:51000-MNAB) at 10 μg/ml (100 μl/well) can bind rat SDC1-Fc, The EC50 of rat SDC1-Fc is 0.4-1.1 μg/ml.
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||Gln 23|
The recombinant rat SDC1/Fc is a disulfide-linked homodimer. The reduced monomer comprises 472 amino acids and has a predicted molecular mass of 51.2 kDa. The apparent molecular mass of the protein is approximately 92 kDa in SDS-PAGE under reducing conditions.
|Formulation:||Lyophilized from sterile PBS, pH7.4.
SDC1 / Syndecan-1 / SYND1 Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
SDC1 / Syndecan-1 / SYND1 Protein Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Syndecan-1/SDC1/CD138||Human||Syndecan-1/SDC1/CD138 Protein, Recombinant||11429-H08H|
|Syndecan-1/SDC1/CD138||Mouse||Syndecan-1/SDC1/CD138 Protein, Recombinant||50641-M08H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R02H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human Syndecan-1 / SDC1 / CD138||IHC-P||Syndecan-1 / SDC1 / CD138 Antibody (Antigen Affinity Purified)||11429-RP02|
|Mouse Syndecan-1 / SDC1 / CD138||WB, ELISA||Syndecan-1 / SDC1 / CD138 Antibody (Antigen Affinity Purified)||50641-RP02|
SDC1 / Syndecan-1 / SYND1 Protein Description
Syndecan-1, also known as SYND1, CD138 and SDC1, is a single-pass type I membrane protein which belongs to the syndecan proteoglycan family. CD138 / Syndecan-1 is well known to be associated with cell proliferation, adhesion, and migration in various types of malignancies. It is a cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. CD138 / Syndecan-1 is a cell-surface heparan sulfate proteoglycan expressed on most epithelial cells, and decreased CD138 expression is associated with increased invasive and metastatic potential in carcinomas. Within the hematopoietic system, CD138 is an excellent marker of plasmacytic differentiation. CD138 / Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. CD138 / Syndecan-1 is a new simple non-invasive marker for predicting liver fibrosis in patients with chronic hepatitis C. The relevance of this marker in combination with other fibrosis markers should be explored. CD138 / Syndecan-1 might contribute to urothelial carcinoma cell survival and progression. It could be a new therapeutic target in urinary bladder cancer.
- O'Connell FP. et al., 2004, Am J Clin Pathol. 121 (2):254-63.
- Gkden N. et al., 2006, Appl Immunohistochem Mol Morphol. 14 (2): 173-7.
- Sun WP. et al., 2007,Cell Mol Immunol. 4 (3): 209-14.
- Zvibel I. et al., 2009, Liver Int. 29 (2): 208-12.
- Shimada K. et al., 2010, Cancer Sci. 101 (1): 155-60.